Za­vante CEO sells his late-stage an­tibi­ot­ic biotech to Nabri­va — grab­bing the helm in the deal

The last time I talked to Za­vante CEO Ted Schroed­er in the spring of 2017, he was steer­ing his an­tibi­ot­ic Zolyd (fos­fomycin for in­jec­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.